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The effects of aerobic, resistance, and
meditative movement exercise on sleep in
individuals with depression: protocol for a
systematic review and network meta-
analysis
Gavin Brupbacher1,2* , Heike Gerger3, Monika Wechsler4, Thea Zander-Schellenberg5, Doris Straus2,
Hildburg Porschke2, Markus Gerber6, Roland von Känel7 and Arno Schmidt-Trucksäss1
Abstract
Background: The main objective of this review is to assess the effects of aerobic, resistance, and meditative
movement exercise on sleep quality in patients with unipolar depression. A secondary goal is to ascertain the
effects on sleep duration, sleepiness, daytime functioning, use of hypnotics, and adverse events.
Methods: A systematic computerized search will be performed in the following online databases: PubMed, EMBASE
(on Ovid), Cochrane Library, PsycINFO (on Ovid), SPORTDiscus (on EBSCOhost), CINHAL (on EBSCOhost), Clinicaltrials.
gov, WHO International Clinical Trials Registry, OpenGrey, and ProQuest Dissertations and Theses. Bibliographies of
all included studies as well as any other relevant reviews identified via the search will be screened. Randomized
trials using aerobic, resistance, or meditative movement exercise interventions which target sleep as a primary or
secondary outcome will be included. The primary outcome will be differences in sleep quality at post-intervention.
Secondary outcomes will be adverse events, differences in sleep duration, daytime sleepiness and functioning, and
the use of hypnotics at post-intervention. Two authors will independently screen the identified records. Disagreement
will be resolved by consensus or if no consensus can be reached by adjudication of a designated third reviewer. Data
extraction will be done independently by two authors using a standardized and piloted data extraction sheet. Bias in
individual studies will be assessed using the revised Cochrane risk of bias tool. The certainty of evidence across all
outcomes will be evaluated using the CINeMA (Confidence in Network Meta-Analysis) framework. A frequentist
network meta-analysis will be conducted. The systematic review and network meta-analysis will be presented
according to the PRISMA for Network Meta-Analyses (PRISMA-NMA) guideline.
Discussion: This systematic review and network meta-analysis will provide a synthesis of the currently available
evidence concerning the effects of aerobic, resistance, and meditative movement exercises on sleep in patients with
unipolar depression. Thereby, we hope to accelerate the consolidation of evidence and inform decision-makers on
potential benefits and harms.
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Background
Description of the condition
Worldwide lifetime prevalence of unipolar depression is esti-
mated to be 10% [1]. Unipolar depression is the leading
cause of burden of disease in middle- and high-income
countries and is projected to become the leading cause
worldwide by 2030 [2]. The economic burden of unipolar
major depression alone was estimated to be $210 billion in
the USA in 2010 [3]. In addition to the direct and often de-
bilitating symptoms, unipolar depression also substantially
increases the risk of all-cause mortality [4] and morbidity [5].
One of the diagnostic criteria for depression according to
DSM-V [6] and ICD-10 [7] is disturbed sleep, i.e., insomnia
or hypersomnia. This is reflected by the high prevalence
(up to 90%) of co-occurring insomnia in individuals with
depression [8]. Insomnia has a negative impact on
health-related quality of life and daytime functioning [9,
10]. Moreover, sleep disturbances have been recognized as
a mechanistic (i.e., causal or bidirectional) process in de-
pression. Sleep problems are an independent risk factor for
depression [11]. Depression and insomnia are linked in a
bidirectional manner [12]. Comorbid sleep disorders have a
negative influence on the disease trajectory in depressive
disorders [13]. Some of the most prevalent residual symp-
toms after treatment response or remission in this clinical
population are insomnia symptoms [14, 15]. This is
pertinent because persistent sleep disorders increase the
likelihood of relapse [13, 16, 17]. Sleep disorders are an
independent risk factor for suicide [18, 19].
According to the British national (NICE) treatment
guidelines, individuals with depression are to be treated
with psychotherapy and pharmacotherapy [20]. However,
antidepressants are of limited efficacy [21] and can cause
considerable adverse effects. In a primary care setting
the number needed to treat (NNT) for improvement of
depressive symptoms by selective serotonin reuptake
inhibitors is approximately seven whereas the number
needed to harm (NNH) (withdrawal due to side effects)
is estimated to be between 20 and 29 [22]. A combin-
ation of antidepressants and benzodiazepine receptor
agonists (Z-drugs) in patients with depression, similarly,
has been shown to be effective (NNT = 10) but causes
considerable adverse events (NNH = 20) [23]. Due to the
frequency of adverse side effects, non-adherence to anti-
depressants is high and associated with decreased remis-
sion rates, increased risk of relapse, and increased health
care utilization [24]. Hypnotics are frequently prescribed
for insomnia. However, they have a poor benefit-to-risk
ratio with serious adverse effects including cognitive im-
pairment, injury from falls and automobile accidents (in-
cluding in younger individuals), cancer, suicide, and
hypnotic withdrawal insomnia [25, 26]. In light of this
evidence, interest in adjuvant and alternative therapies,
especially exercise, has increased in the last decade.
Description of the intervention
The effects of exercise on depressive symptoms have been
summarized in multiple meta-analyses [27–38]. System-
atic reviews found moderate-to-large effect sizes for aer-
obic [28], resistance [36] as well as yoga [35] exercises on
depression. Moreover, no significant differences between
these interventions and antidepressant medication were
found [28, 35]. The effect of other meditative movement
exercises such as qi gong and tai chi seems to be positive,
albeit less pronounced [37, 38]. Aerobic exercise interven-
tions in depressive patients have also been found to
improve cardiorespiratory fitness [27]. This is relevant
because depression is known to increase the risk of
cardiovascular mortality and morbidity [29, 30].
Current data suggest that exercise might be a suitable
therapeutic option to improve sleep quality. Aerobic ex-
ercise has been shown to have positive acute (during the
night immediately following exercise) and chronic (over
several weeks) effects on sleep in healthy individuals
with small-to-moderate effect sizes [39, 40]. These find-
ings have been replicated in populations with sleep com-
plaints [39, 41–43] and chronic disorders [44–49] and
confirmed by a meta-analysis of previous meta-analyses
[50]. A recent meta-analysis also found moderate-to-large
effect sizes for mainly chronic resistance training on sleep
quality [51]. Lastly, numerous meta-analyses show a posi-
tive effect of meditative movement on sleep quality in a
variety of patient [49, 52] and elderly [53] populations.
However, to the knowledge of the authors, no systematic
review concerning the effect of exercise on sleep in
patients with depression has been performed.
Potential mechanisms of action
Although the etiology of insomnia (with or without comor-
bidities) is not yet fully understood, hyperarousal is widely
considered a causal and maintaining factor [54–56].
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Multiple mechanisms of action, including ones which
involve hyperarousal, have been proposed to explain the
effect exercise has on sleep (confer the reviews of
Buman and King (2010) [57] and Uchida et al. 2012 [58]
for aerobic exercise). Insomniacs have been shown to
have impaired thermoregulation [59]. Chronic exercise,
on the other hand, improves thermoregulation [60, 61].
Increased skin temperature, which occurs during and
immediately after acute aerobic [62], resistance [63], and
meditative movement [61, 64] exercise, seems to modu-
late neural circuits in a way which might be conducive
to sleep [65]. Exercise causes changes in the levels of
pro-inflammatory cytokines [66], growth hormone [67,
68], and brain-derived neurotrophic factor [69–71]
which seem to play a role in the regulation of sleep [72–
74]. Aerobic [28], resistance [51], and meditative
movement [75] exercise have positive effects on anxiety
as well as depression and might thereby reduce psycho-
physiological arousal. Although it is not fully understood
why humans sleep, one hypothesis states that humans
sleep to optimize restorative processes [76]. Aerobic and
resistance exercise increase energy expenditure and re-
quire muscle repair, thus stimulating such restorative
processes. Aerobic exercise has also been shown to con-
sistently produce phase shifts (i.e., changes in circadian
rhythm within the 24 h cycle) in individuals of different
ages and fitness levels. This effect has been found in in-
dividuals irrespective of age and cardiorespiratory fitness
as well as independent from the effect of light. [77].
Therefore, aerobic exercise may act as a so-called ‘zeit-
geber’ positively affecting entrainment (i.e., the
synchronization of the endogenous and exogenous
rhythms). It should be noted that it is unclear whether
the mechanisms of action differ between insomniacs
with and without psychiatric comorbidity.
Why it is important to do this review
The rationale for this review can be summarized in four
points. (1) Sleep disturbances are of high prognostic
relevance for remission in depression [11]. (2) Current
therapies have a dissatisfactory benefit-to-risk-ratio. (3)
Exercise has been shown to have positive effects on de-
pression [28, 36, 75] as well as sleep [39, 41, 49, 51, 53].
(4) To the best of our knowledge, no systematic review
has been performed to ascertain the effects of aerobic,
resistance, and meditative movement exercise on sleep
in people with depression.
The main objective of this review is to assess the ef-
fects of aerobic, resistance, and meditative movement
exercise on sleep quality in patients with depression. A
secondary goal is to ascertain the effects of exercise on
sleep duration, sleepiness, daytime functioning, use of
hypnotics, and adverse events (e.g., injuries, cardiovascu-
lar incidences).
Methods
Before initiation of the project, a search in relevant data-
bases (including PROSPERO) showed no prior or on-
going systematic review of this subject. This systematic
review protocol has been reported according to the Pre-
ferred Reporting Items for Systematic Review and
Meta-analysis Protocols (PRISMA-P) guidelines [78] (see
Additional file 1). Accordingly, the protocol for this
study was published in the International Prospective
Register of Systematic Reviews database (PROSPERO)
[79] on 13th February 2019 (PROSPERO CRD420
19115705). Should any amendments to this protocol be
necessary, they will be documented on the PROSPERO
platform. The systematic review and network
meta-analysis itself will be presented according to the
PRISMA Extension Statement for Reporting of System-
atic Reviews Incorporating Network Meta-analyses of
Health Care Interventions [80].
Eligibility criteria
Population
Only studies on adult humans (>= 18 years old) of either
sex with either a medical diagnosis of unipolar depression
or presence of significant depressive symptoms as deter-
mined by a validated instrument (e.g., Beck Depression
Inventory [81], Research Diagnostic Criteria [82], Inter-
national Classification of Disease [7], or Diagnostic and
Statistical Manual of Mental disorders [6]) will be in-
cluded. Studies will be excluded if subjects had another
substantial somatic disorder which might cause the de-
pressive symptoms (i.e., primary symptoms are not
depression) or if subjects were working night-shifts.
Intervention
Included trials must allocate subjects to at least one of the
following: aerobic, resistance, or meditative movement ex-
ercise intervention. Aerobic exercise is defined as “any ex-
ercise that primarily uses the aerobic energy-producing
systems, can improve the capacity and efficiency of these
systems, and is effective for improving cardiorespiratory
endurance” [83]. Resistance exercise is defined as “is exer-
cise that causes muscles to work or hold against an ap-
plied force or weight” [84]. Meditative movement exercise
is defined as a combination of some form of movement or
body positioning, breathing, and relaxation [85]. The
intervention can be acute (a single bout of exercise) or
chronic (repeated exposure). We have not placed restric-
tions on the duration of the intervention period in order
to include the maximum number of trials in this review.
Potential statistical heterogeneity or inconsistency due to
this factor will be explored (see below). No restrictions are
placed on the setting (e.g., laboratory, outdoors), the social
context (e.g., individual, group), or the level of supervision
(e.g., not guided, under the supervision of an exercise
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professional). Exercise can be part of a multicomponent
intervention. Multicomponent interventions in which ex-
ercise was not a dominant part (i.e., exercise was one of
four or more intervention modules) will be excluded.
Comparison
Trials have to allocate participants to aerobic, resistance,
or meditative movement exercise vs. a comparison
group. There are no restrictions on the comparison
group (e.g., pharmacotherapy, psychotherapy, other exer-
cise intervention).
Outcomes
Included trials must measure the effect of aerobic, resist-
ance, or meditative movement exercise on sleep quality.
This can be operationalized using self-reports or obser-
ver ratings.
Study type
In order to be eligible, trials must have employed ran-
domized allocation.
Publication status
Studies are included regardless of whether or not they
are published in a peer-reviewed journal. The use of un-
published trials in reviews is a controversial topic. Re-
views have found that exclusion of gray literature may
lead to an overestimation of effect size [86, 87]. On the
other hand, van Driel et al. (2009) have shown that un-
published trials have poor or unclear methodological
quality [88]. Therefore, methodological quality is consid-
ered when deciding whether the network meta-analysis
is valid and if the number of studies allows it, subgroup
analyses will include methodological quality.
Language
Articles written in English or German will be included. Ar-
ticles in any other language will be included if a translation
is made available. Any article which might be relevant, but
could not be included due to the aforementioned language
constraints will be listed in an appendix.
Information sources
Multiple sources will be used in this systematic review.
A systematic computerized search will be performed in
the following online databases: PubMed (on PubMed.
gov), EMBASE (on Ovid), Cochrane Library (on cochra-
nelibrary-wiley.com), PsycINFO (on Ovid), SPORTDis-
cus (on EBSCOhost), and CINHAL (on EBSCOhost).
OpenGrey (on opengrey.eu) and ProQuest Dissertations
and Theses A&I (on proquest.com) will be searched to in-
clude gray literature. Bibliographies of all included studies
as well as any other relevant reviews identified via the
search will be screened. Clinicaltrials.gov and WHO Inter-
national Clinical Trials Registry will be searched in order
to identify ongoing as well as unpublished studies. Due to
lack of controlled vocabulary and restricted length of
search strings on these websites, a modified query will be
used. Authors of included studies will be contacted via
e-mail in order to inquire whether they know of any other
relevant publications. All databases will be searched from
their inception to the search date.
Search strategy
The search strategy will be constructed using the PICOS
(patient, intervention, comparison, outcome, study
design) framework. The search string will be comprised
of controlled vocabulary whenever possible and free text.
These terms (including appropriate truncation) will be
selected in an iterative scoping search using the PICOS
approach as well as backward and forward chaining. The
study design component will be identified using the
“Cochrane highly sensitive search strategies for identify-
ing randomized trials” [89] and translated according to
the database. Terms within each group will be combined
with a Boolean “OR” and groups will be combined using
a Boolean “AND” command. The PubMed search strat-
egy (see Additional file 2) was adapted according to the
controlled vocabulary in each database (see Add-
itional file 2). The search strategy has been reviewed by
an information scientist from the Basel Medical Univer-
sity Library using the Peer Review of Electronic Search
Strategies (PRESS) guideline [90]. Test searches have
been performed in order to ensure the validity of the
search string.
Study records
Data management
All records identified in the databases will be collected in
the reference management software EndNote® X8 (Thom-
son Reuters, New York, NY). However, deduplication will
be performed using the Systematic Review Assistant-
Deduplication Module. This software has been shown to
have superior sensitivity and specificity in the deduplica-
tion process when compared with EndNote [91].
Selection process
Upon deduplication, records will be screened in two
stages. Firstly, the title and the abstract of all records will
be screened against the aforementioned inclusion and
exclusion criteria (possible assessments: no (an exclusion
criterion is found in title or abstract), maybe or yes (in-
clusion and exclusion cannot be definitively assessed or
study is deemed to fulfill all criteria). Secondly, full texts
of all articles which were not excluded in the first stage
will be reviewed to determine whether all relevant
criteria are met. Both stages will be performed
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independently by two reviewers (GB and TZS) who will
not be blinded to any information (e.g., author, journal,
institutions). We do not blind the reviewers, since there
is empirical evidence that blinding has little to no effect
in meta-analyses [92]. Disagreement will be resolved by
consensus. If no consensus can be reached, disagreement
will be resolved by adjudication of a designated third re-
viewer (AST). An online systematic review software,
Covidence [93], will be used to judge eligibility, resolve
issues, and document the screening processes.
Before the actual screening process begins, both re-
viewers will screen 50 randomly selected articles in order
to assure an adequate inter-rater agreement (Cohen’s kappa
> 0.80). Should this goal not be reached, this process will be
repeated until the defined level of agreement is reached.
Inter-rater agreement will be reported using raw agreement
in percent and Cohen’s kappa since both have respective
strengths and limitations [94]. Furthermore, the number of
disagreements solved by discussion and arbitration by the
third reviewer will be stated. A flow diagram according to
the PRISMA guidelines [95] will illustrate the number and
the reasons for excluded and included citations.
Data collection process
A standardized data extraction form will be created in
Excel on the basis of the Cochrane Consumers and
Communication Review Group’s data extraction tem-
plate [96] and the DECiMAL guide [97]. This form will
be tested against a subset of studies found in the scoping
search and adapted accordingly before data extraction.
Both reviewers (GB and TZS) will extract data inde-
pendently. Authors will be contacted should data be
missing. (The corresponding author will initially be con-
tacted via e-mail with one additional reminder e-mail,
should there be no response within 2 weeks. Subse-
quently, the other authors will be contacted). Disagree-
ment will be resolved by consensus upon consulting the
original paper or if no consensus can be reached,
disagreement will be resolved by adjudication of a desig-
nated third reviewer (AST). To avoid the inclusion of
double publications of one study, authors, treatment
comparisons, sample sizes, and outcomes of the
included studies will be compared. We will include the
publication which has the most information pertinent to
the meta-analysis.
Data items
For the calculation of relative treatment effects group
means, corresponding standard deviations and group
sizes will be extracted primarily. In case one of these
values was missing, other statistical data that can be
converted into means and standard deviations will be ex-
tracted. Conversions will be calculated according to for-
mulas provided, e.g., [98, 99]. If standard deviations
cannot be calculated from the available study informa-
tion, we will impute them using the standard deviations
reported in the other included studies [100]. We will
conduct sensitivity analyses excluding studies in which
standard deviations had to be imputed. If the N was
missing in the table of analysis, we will use the N of the
descriptive statistics. If studies report medians and inter-
quartile ranges, a normal distribution will be assumed, if
not indicated otherwise, to convert these values to
means and standard deviations [98]. If studies only
report adjusted outcome values, data will be extracted,
but sensitivity analyses will be calculated without these
studies to check for possible bias. We plan to extract the
effect size provided by the study authors only if no other
information was available for effect size calculation. If it
is not possible to impute appropriate measures for the
calculation of effect sizes, and no effect sizes are
reported we will contact the authors.
Among others, the following information will be ex-
tracted from each study:
– Information on the study itself (e.g., title, publication
date, authors)
– Methods (e.g., objective, design, number of
participants included in the analysis)
– Risk of bias assessment (Cochrane revised risk of
bias tool) [101]
– Setting (non-clinical vs. clinical, inpatient vs.
outpatient)
– Participants (i.e., mean age, inclusion and exclusion
criteria, severity of depression, diagnostic tool)
– Intervention (i.e., frequency, intensity, duration, type
of exercise)
– Comparisons (comparator conditions)
– Outcomes (primary and secondary outcomes,
adverse events)
– Results (mean and standard deviation of outcomes
pre- and post-intervention as well as follow-up)
– Self-report vs. observer rating
– Duration of follow-up
Outcomes and prioritization
The primary outcome will be standardized mean differ-
ences (SMD) of sleep quality at post-exercise-intervention
and at the last available follow-up assessment, measured
by self-reports (e.g., PSQI [102], ISI [103]) or clinician rat-
ings (sleep-related HAM-D items [104]).
Secondary outcomes will be:
1. SMD of sleep duration at post-exercise intervention
and at last available follow-up assessment (mea-
sured objectively or subjectively)
2. SMD of daytime functioning at post-exercise inter-
vention and at last available follow-up assessment,
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measured by self-reports (e.g., Insomnia impact
scale [105])
3. SMD of sleepiness at post-intervention and at last
available follow-up assessment, measured by self-
reports (e.g., Epworth sleepiness scale [106])
4. SMD of hypnotics use at post-intervention and at
last available follow-up assessment, measured by
self-reports
5. SMD of any adverse events as defined by Good
Clinical Practice guidelines [107] (e.g., pain, falls,
injuries, dizziness, myocardial infarction)
The rationale for the selection of the primary outcome
is that perceived sleep quality, i.e., difficulties initiating
or maintaining sleep or early morning awakening is one
of the main complaints in insomnia. Reduced sleep dur-
ation [108] and daytime impairments are a further im-
portant category of complaints, markedly increasing the
perceived need for treatment [109]. Adverse events must
be considered in order to inform decision-makers on the
benefit-to-risk ratio of an exercise intervention.
Risk of bias in individual studies
The risk of bias will be evaluated independently by two re-
viewers (GB and TZS) at the study level. Disagreement will
be resolved by consensus or if no consensus can be reached,
disagreement will be resolved by adjudication of a desig-
nated third reviewer (AST). Bias will be assessed using the
revised Cochrane risk of bias tool [101]. This tool assesses
five domains: (1) randomization process, (2) deviations
from intended interventions, (3) missing outcome data, (4)
measurement of outcomes, and (5) selection of reported in-
terventions. The three possible judgments are possible: low
risk, some concerns, and high risk of bias. A summary table
of bias assessment on study level will be included in the
publication. These assessments will contribute to the evalu-
ation of overall confidence in the findings of the network
meta-analysis using the CINeMA framework [110].
Data synthesis
Data will be synthesized descriptively. A summary table of
included studies will entail information on the authors,
population characteristics (diagnostic criteria, baseline
severity of sleep quality, depression, age, and numbers), in-
terventions (exposure in each group), outcomes measures
used, and results (sleep quality, sleep duration). Network
meta-analysis will be performed. Statistical (number of
studies and heterogeneity of results), clinical (heteroge-
neous populations), and methodological (low quality of
trials or follow-up duration) aspects will be considered to
decide whether network meta-analysis is valid. If network
meta-analysis results must be deemed methodologically
inaccurate, a pairwise meta-analysis will be considered.
Should a pairwise meta-analysis also not be possible, stud-
ies will be summarized narratively.
The package netmeta [111] for the open-source soft-
ware environment R [112] will be used to calculate net-
work meta-analyses within a frequentist framework.
A network will be created including all available jointly
randomizable treatments. We assume that any patient that
meets all inclusion criteria is likely, in principle, to be
randomized to any of the interventions in the synthesis
comparator set.
We will address the assumption of transitivity which
underlies network meta-analysis [113], by (1) assessing
whether the included interventions are similar across
studies using a different design, and (2) checking
whether the distribution of potential moderators is
balanced across comparisons [114]. A priori we have
defined depression severity, comorbidities, age, and
gender as potential effect modifiers and will evaluate the
comparability of the respective characteristics across
comparisons qualitatively.
We expect considerable diversity of outcome measures
and will, therefore, calculate standardized mean differ-
ences (SMD) using Hedge’s g with 95% confidence inter-
vals [115]. SMD is the mean difference between groups
divided by the pooled standard deviation. The effect size
measure allows comparison of effect sizes across similar
measurements of a single outcome. The conventional
and somewhat arbitrary classification of SMD proposed
by Cohen (1988) [116] has been expanded to include
very small (.01), small (0.2), medium (0.5), large (0.8),
very large (1.2), and huge (2.0) effect sizes [117].
Random-effects pairwise SMDs across studies will be
calculated based on the available comparisons between
treatment and comparator treatments [118]. Inverse
variance weighting is used for pooling. In addition, indir-
ect evidence will be estimated using the entire network
of evidence. Random-effects netmeta accounts for de-
pendencies between comparisons in case of multi-arm
trials [119]. The command pairwise will be used in case
of multi-arm trials, in order to transform the dataset to
the comparison level, which is needed for conducting
the network meta-analysis.
The primary outcome will be SMD of sleep quality
assessed via self- or observer-reported measures. If more
than one primary outcome is reported, the most fre-
quently used scale will be included in the analysis to re-
duce between-study heterogeneity. If possible, we will
assess the association between instruments and changes
in sleep quality. Two individual analyses will be run for
the outcome data at the end of treatment, and the last
available follow-up. Separate network meta-analyses will
be conducted for secondary outcomes if possible. Results
from network meta-analysis will be presented as sum-
mary SMD for each possible pair of treatments.
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Whenever possible, measures of uncertainty will be re-
ported in the form of the 95% confidence interval and
95% prediction interval.
To calculate statistical heterogeneity between studies
on the pairwise level, the Q statistic will be used [89].
Further τ2 will be analyzed to estimate the variance
caused by the distribution of the true study means [120].
I2 will be evaluated to indicate the amount of observed
variance that can be attributed to between-study hetero-
geneity [121]. I2 and the corresponding confidence inter-
val can be interpreted as the percentage of overall
heterogeneity that is due to variation of the true effects.
An I2 value of 0% to 40% might not be important, 30 to
60% may represent moderate heterogeneity, 50 to 90%
may represent substantial heterogeneity, and 75 to 100%
considerable heterogeneity [89]. In NMA, we will as-
sume a common estimate for the heterogeneity variance
across the different comparisons.
Local and global methods will be used to detect incon-
sistency [122]. The presence of inconsistency will be eval-
uated using the following approaches: (1) locally using the
netsplit command (i.e., testing the difference between esti-
mates derived from direct evidence and estimates derived
from indirect estimates for statistical significance) and (2)
globally using the decomp.design command (i.e., using the
design-by-treatment interaction model). For this purpose,
the total Q statistic (i.e., the measure of total heterogen-
eity/inconsistency in the network) will be decomposed to
an inconsistency factor (between designs) and a hetero-
geneity factor (within designs). We will compare the mag-
nitude of heterogeneity between consistency and
inconsistency models to determine how much heterogen-
eity will be explained by inconsistency. We will do this by
testing the residual inconsistency, which remains under
the assumption of a full design by treatment interaction
model for statistical significance.
In the case of statistical heterogeneity or inconsistency
between results from individual studies, we will investi-
gate the potential impact of the following trial-level ef-
fect modifiers: (1) year of publication, (2) study precision
(i.e., sample size), (3) studies reporting non-adjusted vs.
adjusted means, (4) studies with imputed standard devia-
tions vs. studies which reported standard deviations. If
the number of studies allows it, theoretically driven sub-
group analyses will be done according to population
(e.g., severity of depression), duration of intervention,
duration of follow-up, outcome characteristics (i.e., self-
vs. observer ratings, objective vs. subjective sleep dur-
ation), and methodological quality.
Meta-biases and confidence in cumulative evidence
The confidence in the network meta-analyses will be es-
timated using the Confidence in Network Meta-Analysis
(CINeMA) framework [110]. This includes study
limitation, indirectness, inconsistency (heterogeneity, in-
coherence), imprecision, and publication bias. Publica-
tion bias will be assessed according to the GRADE
guideline [123] and by comparing eligible trials identified
in registries (e.g., clinicaltrials.gov) with published data.
Selective reporting bias will be assessed by comparing
protocols (if available) and reports of trials.
Dissemination
The results will be published in a peer-reviewed journal
and presented at conferences as well as invited talks.
Discussion
This systematic review will provide an overview of the
current state of evidence concerning the effects of aerobic
exercise on sleep in patients with depression. To the best
of our knowledge, this will be the first systematic review
concerning this topic. The primary outcomes analyzed will
provide evidence on the benefits, i.e., duration and per-
ceived quality of sleep, as well as serious harms. Secondary
outcomes will provide information on sleep-related con-
structs such as daytime functioning and sleepiness as well
as other adverse outcomes. Furthermore, gaps in the
current literature will be identified, and recommendations
for future avenues of research will be given. Strengths of
this systematic review include the search in multiple data-
bases according to the interdisciplinary nature of the sub-
ject, the systematic approach including screening, data
extraction, and quality assessment by two independent re-
viewers, as well as transparency in reporting according to
guidelines. The main limitation is the language restriction
to German and English which might lead to language bias.
Considering the importance of sleep disturbances in
depression, we hope that this systematic review can accel-
erate the consolidation of evidence, such that decision-
makers (patients, health-care professionals, and policy-
makers) are provided with high-quality evidence to facili-
tate decisions on whether and how to implement aerobic,
resistance, or meditative movement exercises as a treat-
ment module for patients with depression.
Current stage of systematic review
PROSPERO stage 1, preliminary searches completed.
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